Company Senti Biosciences, Inc.

Equities

SNTI

US81726A1007

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
0.2787 ^USD	-0.78%		-9.37%	-57.77%

Apr. 26	Senti Biosciences, Inc. Announces Resignation of Deborah Knobelman as Chief Financial Officer, Effective May 3, 2024	CI
Apr. 26	Senti Biosciences, Inc. Announces Resignation of Deborah Knobelman as Treasurer and Head of Corporate Development, Effective May 3, 2024	CI

Senti Biosciences, Inc. is a clinical-stage biotechnology company. It is developing cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. It is focused on off-the-shelf CAR-NK cell therapy programs for oncology indications. Its lead product candidate, SENTI-202, is a potential Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia, while sparing healthy bone marrow cells. Its second clinical development program is SENTI-301A, a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy. SENTI-202 has been designed to incorporate three chimeric proteins using a Logic Gated gene circuit and delivered through a single retrovirus. SENTI-301A is a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy designed for the treatment of advanced GPC3 positive tumors.

Number of employees: 48

USD in Million	2022	Weight	2023	Weight	Delta
Contract Revenue 77.2 %	3	76.7 %	2	77.2 %	-39.81%
Grant 22.8 %	1	23.3 %	1	22.8 %	-41.70%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	4	100.0 %	3	100.0 %	-40.25%

Managers	Title	Age	Since
Timothy Lu FOU	Founder	43	16-06-08
Deborah Knobelman DFI	Director of Finance/CFO	51	21-04-30
Kanya Rajangam CTO	Chief Tech/Sci/R&D Officer	50	22-06-30

Members of the board	Title	Age	Since
Susan Berland BRD	Director/Board Member	69	21-05-31
Ed Mathers Mathers BRD	Director/Board Member	64	16-06-30
Omid Farokhzad BRD	Director/Board Member	55	22-06-07
James Collins BRD	Director/Board Member	58	22-06-07
Thomas P. Chung BRD	Director/Board Member	-	22-08-31
Timothy Lu FOU	Founder	43	16-06-08
Brenda Cooperstone BRD	Director/Board Member	59	19-09-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	45,755,021	35,505,472 ( 77.60 %)	0	77.60 %

Name	Equities	%	Valuation
BAYER AG 12.85 %	5,878,488	12.85 %	2 M $
NEA Management Co. LLC 9.674 %	4,426,151	9.674 %	2 M $
Eight Enterprises LLC 5.546 %	2,537,558	5.546 %	956 659 $
Omid Farokhzad 4.256 %	1,947,403	4.256 %	734 171 $
Timothy Lu 4.201 %	1,922,276	4.201 %	724 698 $
ARK Investment Management LLC 3.564 %	1,630,922	3.564 %	614 858 $
Philip Lee 2.047 %	936,424	2.047 %	353 032 $
Vanguard Group, Inc. (Subfiler) 1.545 %	707,052	1.545 %	266 559 $
INTEL CORPORATION 1.302 %	595,665	1.302 %	224 566 $
Triatomic Management LP 0.6787 %	310,533	0.6787 %	117 071 $

Senti Biosciences, Inc.

2 Corporate Drive First Floor

94080, South San Francisco

http://www.sentibio.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
SENTI BIOSCIENCES, INC.	-57.77%	13.27M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs